Baxalta Inc announced the publication of pivotal phase III data for BAX 111 (recombinant von Willebrand Factor) in Blood, the...
Baxalta has announced initial results from a Phase III clinical trial of Adynovate (recombinant factor VIII), an extended circulating half-life...
Baxalta Incorporated announced that the FDA has approved Vonvendi [von Willebrand factor (Recombinant)]. Vonvendi is the first and only recombinant...
This non-controlled multicentre phase II study is designed to assess the safety and to describe (in relation to children of...
Ad26.COV2-S [recombinant] a single-dose coronavirus vaccine from Janssen, part of Johnson & Johnson, has been approved by the MHRA (UK) and is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
New Phase III data from Bayer HealthCare's LEOPOLD Kids clinical trial investigating the safety and efficacy of BAY 81-8973, otherwise...
Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/IIa first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July.
CSL Behring announced that the FDA has approved Idelvion [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting albumin...